[go: up one dir, main page]

GB201720401D0 - Means and methods to treat torsin related neurologicl diseases - Google Patents

Means and methods to treat torsin related neurologicl diseases

Info

Publication number
GB201720401D0
GB201720401D0 GBGB1720401.7A GB201720401A GB201720401D0 GB 201720401 D0 GB201720401 D0 GB 201720401D0 GB 201720401 A GB201720401 A GB 201720401A GB 201720401 D0 GB201720401 D0 GB 201720401D0
Authority
GB
United Kingdom
Prior art keywords
neurologicl
torsin
diseases
treat
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1720401.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven, Vlaams Instituut voor Biotechnologie VIB filed Critical Katholieke Universiteit Leuven
Priority to GBGB1720401.7A priority Critical patent/GB201720401D0/en
Publication of GB201720401D0 publication Critical patent/GB201720401D0/en
Priority to PCT/EP2018/083784 priority patent/WO2019110728A1/en
Priority to EP18816009.7A priority patent/EP3720961A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03004Phosphatidate phosphatase (3.1.3.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1720401.7A 2017-12-07 2017-12-07 Means and methods to treat torsin related neurologicl diseases Ceased GB201720401D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB1720401.7A GB201720401D0 (en) 2017-12-07 2017-12-07 Means and methods to treat torsin related neurologicl diseases
PCT/EP2018/083784 WO2019110728A1 (en) 2017-12-07 2018-12-06 Means and methods to treat torsin related neurological diseases
EP18816009.7A EP3720961A1 (en) 2017-12-07 2018-12-06 Means and methods to treat torsin related neurological diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1720401.7A GB201720401D0 (en) 2017-12-07 2017-12-07 Means and methods to treat torsin related neurologicl diseases

Publications (1)

Publication Number Publication Date
GB201720401D0 true GB201720401D0 (en) 2018-01-24

Family

ID=61007310

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1720401.7A Ceased GB201720401D0 (en) 2017-12-07 2017-12-07 Means and methods to treat torsin related neurologicl diseases

Country Status (3)

Country Link
EP (1) EP3720961A1 (en)
GB (1) GB201720401D0 (en)
WO (1) WO2019110728A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802775C (en) * 2010-06-17 2019-09-24 Vib Vzw Increased protein expression through increased membrane formation
CL2011000273A1 (en) * 2011-02-08 2011-06-17 Univ Pontificia Catolica Chile Use of a phosphatidic acid phosphohydrolase enzyme (pap) inhibitor or combination of inhibitors, in which the inhibitor is d (+) propranolol, and the combination is racemic mixture of propranolol od (+) propranolol together with desipramine, to prepare a Useful medicine in the treatment of cancer.
US10881746B2 (en) * 2016-06-06 2021-01-05 Vib Vzw Means and methods to treat dystonia

Also Published As

Publication number Publication date
WO2019110728A1 (en) 2019-06-13
EP3720961A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
IL283799B (en) Compounds and methods of treating rna-mediated diseases
PL3349783T3 (en) Compositions and methods relating to the treatment of diseases
SG11201608077PA (en) Treatment of nafld and nash
IL253244A0 (en) Methods of treating retinal diseases
IL239735A0 (en) Toxic aldehyde related diseases and treatment
GB201705725D0 (en) Animal models and therapeutic molecules
ZA201702214B (en) Methods of using interleukin-10 for treating diseases and disorders
EP3030275A4 (en) Method of treating peripheral artery diseases in lower limbs
IL249098A0 (en) Methods and compositions for treating allergy and inflammatory diseases
IL275517A (en) Methods and combination therapy to treat cancer
EP3030276A4 (en) Method of treating peripheral artery diseases in lower limbs
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
EP3030274A4 (en) Method of treating peripheral artery diseases in lower limbs
IL270011B (en) Therapeutic compounds and methods
SI3722291T1 (en) Indolinone compounds and their use in the treatment of fibrotic diseases
SG11201704829QA (en) Methods and compositions for treating brain diseases
IL277911A (en) Treating ige-mediated allergic diseases
IL253847A0 (en) Methods of treating diseases
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
EP2964227A4 (en) Treatment and prophylaxis of kidney diseases
EP3523433C0 (en) Means and methods to treat inflammatory diseases
GB201617622D0 (en) Means and methods to treat inflammation
IL255012A0 (en) Compositopns and methods for treating skin conditions
IL252707B (en) Compositions and methods for treating diseases and conditions

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)